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Abstract
Invasive pituitary adenomas and pituitary carcinomas are clinically indistinguishable until 
identification of metastases. Optimal management and survival outcomes for both are not clearly 
defined. The purpose of this study is to use the Surveillance, Epidemiology, and End Results 
(SEER) database to report patterns of care and compare survival outcomes in a large series of 
patients with invasive adenomas or pituitary carcinomas. One hundred seventeen patients 
diagnosed between 1973 and 2008 with pituitary adenomas/adenocarcinomas were included. 
Eighty-three invasive adenomas and seven pituitary carcinomas were analyzed for survival 
outcomes. Analyzed prognostic factors included age, sex, race, histology, tumor extent, and 
treatment. A significant decrease in survival was observed among carcinomas compared to 
invasive adenomas at 1, 2, and 5 years (p=0.047, 0.001, and 0.009). Only non-white race, male 
gender, and age ≥65 were significant negative prognostic factors for invasive adenomas (p=0.013, 
0.033, and <0.001, respectively). There was no survival advantage to radiation therapy in treating 
adenomas at 5, 10, 20, or 30 years (p=0.778, 0.960, 0.236, and 0.971). In conclusion, pituitary 
carcinoma patients exhibit worse overall survival than invasive adenoma patients. This highlights 
the need for improved diagnostic methods for the sellar phase to allow for potentially more 
aggressive treatment approaches.
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Introduction
Invasive adenomas are benign pituitary tumors that infiltrate the dura mater, cranial bone, or 
sphenoid sinus. Gross invasion at time of operation is observed in up to 35 % of pituitary 
adenomas [1-3]. Although not malignant, invasive adenomas exhibit aggressive biological 
behavior. In contrast, pituitary carcinomas are defined as tumors of the pituitary gland 
exhibiting cerebrospinal and/or systemic metastasis. They are rare and account for only 0.1 
to 0.2 % of pituitary tumors [4].
Differentiating locally aggressive adenomas from carcinomas in their sellar phase can be 
difficult because it is unusual for a patient to have metastases at the time of initial 
presentation. Attempts have been made to define morphologic features and molecular 
markers more commonly associated with invasive adenoma or pituitary carcinoma to help 
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predict tumor behavior and discriminate between the two prior to identification of metastatic 
disease. These include quantification of the degree of cytologic atypia and mitotic activity, 
examination of proliferation markers such as Ki-67 using the MIB-1 antibody and cell-cycle 
molecules such as p27 and galectin-3, and gene expression of p53, MGMT, and MMP-9 
[5-9]. Several patterns have been identified. For example, Thapar et al. noted increased 
MIB-1 indices in carcinomas (12 %) compared to invasive adenomas (4.5 %) and 
noninvasive adenomas (1 %) [10]. In a separate study, overexpression of the p53 
oncoprotein was found to occur in 100 % of carcinomas but only 15 % of invasive 
adenomas and 0 % of noninvasive adenomas examined [11]. Despite such findings, there are 
currently no consistent patterns in immunohistochemistry, cell histology, or radiological 
appearance that differentiate invasive adenoma from pituitary carcinoma [12]. The difficulty 
distinguishing between the tumors is highlighted by the introduction of an intermediate 
category of “atypical adenoma” between adenoma and carcinoma by the World Health 
Organization. The atypical classification is used for those adenomas exhibiting a MIB-1 
proliferative index greater than 3 %, significant p53 immunoreactivity, and increased mitotic 
activity [13]. Recently, genetic analysis of pituitary carcinomas has shown an average of 9.3 
chromosomal imbalances per tumor (7 gains vs. 1.3 losses) with the most common changes 
being gains of chromosomes 5, 7p, and 14q [4]. While such analysis of invasive adenomas 
may in the future enable better identification of those tumors likely to undergo malignant 
transformation and eventual metastatic dissemination, it is not routinely available in clinical 
practice [14].
Current treatment approaches for both invasive adenoma and pituitary carcinoma include 
surgical debulking, definitive or adjuvant radiation therapy, or medical management. 
Optimal management of these tumors is not clearly defined. Similarly, survival outcomes 
specifically in patients with invasive adenoma and pituitary carcinoma are relatively 
unknown and generally based on case reports or small single institution series [4, 9, 15-19].
The purpose of this study is to use the Surveillance, Epidemiology, and End Results (SEER) 
database to report patterns of care and to compare survival outcomes according to patient 
characteristics, tumor characteristics, and treatment received in a large series of patients with 
invasive adenoma or pituitary carcinoma.
Methods
Study participants
The National Cancer Institute’s SEER database November 2010 submission [20] was used. 
Three hundred twenty-two patients with primary site pituitary tumors (ICD-0-3 Code C75.1) 
classified as exhibiting malignant behavior and diagnosed between January 1, 1973, and 
December 31, 2008, were identified. As there is no code for invasive adenomas specifically, 
only those exhibiting malignant behavior were included in the analysis as this is 
synonymous with invasion for SEER database coding. All tumors were further stratified 
based on pathologic extent of disease when available; otherwise, extent of disease was based 
on radiologic findings. Only malignant tumors with documented metastases were classified 
as pituitary carcinomas; all others were classified as invasive adenomas. For frequency 
analysis of patient demographics, tumor characteristics, and treatment received, patients 
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with histology other than adenoma or adenocarcinoma (M8140–M8389) were excluded, 
resulting in a study population of 117 (110 invasive adenomas, 7 pituitary carcinomas). 
From this subset of patients, the survival analysis included only actively followed patients 
with microscopically confirmed adenomas (n=90) or adenocarcinomas (n=7) with further 
exclusion of seven patients with a diagnosis of invasive pituitary adenoma obtained through 
death certificate or autopsy, those alive with no survival time, and those with multiple 
primaries. No patient in the carcinoma group required exclusion for these reasons. 
Therefore, 83 invasive adenomas and 7 pituitary carcinomas were included in the overall 
survival analysis.
Outcome measures
Overall survival was defined as the time from diagnosis until death or the time of last 
follow-up. Those cases lost to follow-up were censored by SEER. Non-survival included 
death from all causes. Prognostic factors included age (<65, ≥65), sex (male, female), race 
(white, non-white), histology according to ICD-0-3 codes (adenoma/adenocarcinoma NOS, 
neuroendocrine adenoma/carcinoma, chromophobe adenoma/carcinoma, pituitary adenoma/
carcinoma NOS, acidophil adenoma/carcinoma), tumor extent (confined to gland of origin, 
localized, spread to adjacent connective tissue or organ, distant metastases), and treatment 
(surgery with and without radiation therapy, any radiation therapy, no radiation).
Surgical technique
Multiple codes are available in the SEER database for classifying the surgical approach 
used. For the purpose of analysis, these techniques were classified into three main groups 
based on the extent of resection. Those classified as incisional, needle, or aspiration biopsy 
include only those tumors for which surgical resection was done for pathologic diagnosis 
only. The gross tumor resection (GTR) group includes only those tumors that underwent 
complete surgical removal. The simple tumor resection (STR) category includes those 
tumors that underwent incomplete resection, classified in SEER as simple or partial 
removal, debulking, or excisional biopsy or removal.
Statistical analysis
In the absence of raw data from SEER, we compared the time-specific actuarial rates of 
observed survival using Fisher’s exact test. Observed survival rates were obtained using 
SEER*Stat version 7.0.4 [21]. Statistical significance was done using Stata Statistical 
Software: Release 9 [22]. Statistical significance was defined as a p value less than 0.05.
Results
Invasive adenoma
Patient, tumor, and treatment characteristics—Patient characteristics, tumor 
characteristics, and treatment received for the 117 patients in our series are summarized in 
Tables 1, 2, and 3, respectively. There was a slight female predominance (ratio 1.12) in 
invasive adenoma patients. The median age at diagnosis was 52.5 (range 1–85+). Seventy-
eight percent of patients with invasive adenoma were white.
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Sixty-nine (76 %) invasive adenomas underwent surgical resection after 1983, with some 
patients having multiple resections. Thirty-four (41 %) invasive adenomas were treated with 
STR alone, 20 (24 %) received STR plus radiation, 2 (2 %) received radiation therapy alone, 
8 (10 %) had neither STR nor radiation therapy, and 19 (23 %) were treated with a 
combination other than those listed above.
Thirty percent of patients with invasive adenoma received external beam radiation therapy 
(EBRT).
Survival outcomes—Overall survival rates for invasive adenoma were 89.1, 87.7, 79.0, 
and 65.5 % at 1, 2, 5, and 10 years, respectively (Fig. 1a). A statistically significant 
difference in survival between invasive adenoma and carcinoma was observed at 1, 2, and 5 
years (p=0.047, 0.001, and 0.009, respectively). No statistically significant difference in 
survival was observed at 10 years (p=0.099). Similarly, the extent of disease (confined to 
gland, localized, invading adjacent connective tissue or organ, distant metastases) 
significantly impacted survival at 1, 2, and 5 years (p=0.034, 0.001, 0.025, respectively).
Younger age (<65) at diagnosis of invasive adenoma conferred a statistically significant 
survival advantage at 10, 15, 20, and 30 years with survival rates of 74.8, 60.0, 56.0, and 
46.8 % compared to those aged ≥65 who had survival rates of 17.2, 0, 0, and 0 % (p<0.001, 
0.001, 0.001, and =0.001, respectively) (Fig. 1b). Women had significantly better overall 
survival than men (79.1 vs. 54.1 % at 12 months, p=0.033, and 51.9 vs. 29.2 % at 36 
months, p=0.047). White race conferred a survival advantage over nonwhite patients (93.8 
vs. 68.8 % at 12 months, p=0.013, and 92.0 vs. 68.8 % at 24 months, p= 0.022). Observed 
survival at 5 years did not significantly differ among the various histologic subtypes (Table 
4).
There was no difference in survival between patients treated with radiation therapy and 
those who were not (83.5, 81.4, 55.9, and 55.9 % vs. 79.1, 70.6, 46.8, and 46.8 % at 5, 10, 
20, and 30 years, NS). Likewise, patients treated with radiation therapy in addition to STR 
did not demonstrate improved survival over those treated with STR alone at 5, 10, 20, or 30 
years (82.1, 65.7, 47.9, and 38.3 % vs. 80.7, 76.0, 48.2, and 48.2 %, NS).
Pituitary carcinoma
Patient, tumor, and treatment characteristics—There was a slight female 
predominance (ratio 1.33) for patients with pituitary carcinoma. The median age at diagnosis 
was 63 (range 18–78). Seventy-one percent of patients with pituitary carcinoma were white. 
Three (50 %) underwent surgical resection after 1983. One patient with pituitary carcinoma 
received EBRT.
Survival outcomes—Overall survival rates for pituitary carcinoma were 57.1, 28.6, 28.6, 
and 28.6 % at 1, 2, 5, and 10 years respectively (Fig. 1a). Due to the small sample size, 
statistical significance of prognostic factors in patients with pituitary carcinoma was not 
analyzed.
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Discussion
We used the SEER database to present the largest series of patients with invasive adenoma 
and pituitary carcinoma published to date. We found that the overall survival in patients with 
pituitary carcinomas was significantly worse than in patients with invasive adenomas. This 
finding is consistent with prior studies demonstrating poor prognosis in patients with 
pituitary carcinoma [4, 5, 9, 18, 19]. The difference in outcome highlights the need for 
improved diagnostic techniques and identification of molecular or radiological markers to 
differentiate invasive adenoma from early carcinoma in the sellar phase in order to allow 
improved therapeutic options. The ability to predict tumor behavior and modify treatment 
accordingly may result in improved local control and overall survival as tumor 
aggressiveness and increased extent of invasion have been shown to have a statistically 
significant association with tumor recurrence or progression [23].
The data presented in this paper suggests that prognosis in patients with invasive adenoma is 
related to several factors. First, reduced overall survival was found in patients with age ≥65. 
This is interesting as although Grossman et al. reported increased odds of death among 
patients >80 years old undergoing pituitary resection relative to 65–69-year olds [24], 
several other studies have shown that age alone does not result in increased treatment-
associated morbidity in this patient population [25-27]. For example, two other studies 
examining the perioperative risk associated with transsphenoidal surgery for pituitary 
tumors in elderly patients reported that surgery was well-tolerated in all patients. No 
perioperative mortality or severe anesthesiological complications were reported, concluding 
that age alone should not be a contraindication to aggressive management of these tumors 
[28, 29]. The survival detriment associated with age in this study may reflect more 
aggressive tumor biology in these patients or perhaps a differential treatment approach such 
that elderly patients were treated less aggressively. Alternatively, since nonsurvival included 
death from all causes, elderly patients may have other medical comorbidities which are not 
accounted for in this SEER database analysis leading to poorer overall survival.
Second, women in this study exhibited significantly better overall survival compared to men 
at 12 months. This is consistent with prior studies that have demonstrated worse outcomes in 
men with prolactin-secreting adenomas compared to women [30, 31]. However, a separate 
study examining gender-related differences in nonfunctioning adenomas found significantly 
worse outcomes in women compared to men [32]. It therefore appears that the effect of 
gender may be confounded by the histology of the tumor.
Interestingly, we found no difference in survival between patients who received radiation 
therapy and those who did not. The 5, 10, 20, and 30-year survival rates were higher in 
patients treated with EBRT compared to those who did not receive EBRT (83.5, 81.4, 55.9, 
and 55.9 % vs. 79.1, 70.6, 46.8, and 46.8 %), but this difference was not statistically 
significant. Survival rates were lower at 10, 20, and 30 years for those patients treated with 
adjuvant radiation therapy (RT) compared to those not receiving RT (65.7, 47.9, and 38.3 % 
vs. 76.0, 48.2, and 48.2 %). This may reflect a preferential administration of therapy in 
patients with more aggressive tumors.
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This study has several limitations based on the limitations of the SEER database. For 
example, information on secretory function or molecular characteristics of the tumors is not 
available. Thus, this study is restricted to invasive adenomas and carcinomas rather than the 
hormonal type or atypical variant. However, the significance of tumor molecular 
characteristics as a prognostic marker should not be overlooked. For example, estimation of 
Ki-67 percentage has been shown to correlate best with invasiveness and prognosis with the 
majority of invasive adenomas having Ki-67 index of less than 10 % [10]. Thus, a Ki-67 
index greater than 10 % should raise concern for the malignant potential of a tumor as a high 
Ki-67 percentage appears to predict rapid tumor progression [14, 33]. Additionally, the 
presence of p53 expression should be determined as the predictive value of this, and an 
increased Ki-67 percentage is likely superior to either alone [14].
An additional limitation of the SEER database is that the data collected is based on coding 
from patient medical records. With no pathological data available for review, there is no 
means of confirming a diagnosis. Also, there is no code for invasive adenomas specifically. 
We were therefore required to identify pituitary tumors likely to be invasive based on tumor 
behavior and extent of disease. Moreover, given that metastases are usually not present at 
first recognition of a pituitary carcinoma, it is unknown if an initial diagnosis of an adenoma 
was ever later revised to reflect the discovery of metastases. If not, many of the tumors in 
this study identified as invasive adenomas may actually be carcinomas in their sellar phase. 
Similarly, given the relatively long survival of these patients, it is possible that many 
patients ultimately succumb to alternative diseases.
Similarly, several important treatment details are not included in the SEER database. As 
such, we do not report data on medical therapy or chemotherapy. Furthermore, not all 
variables that are available in SEER are reliably reported. This combined with the small 
sample size limits the power for possible analyses.
Nonetheless, to our knowledge, this study is the largest study to report long-term survival 
outcomes in patients with invasive adenoma and is the second largest series to date of 
patients with pituitary carcinoma. It highlights the need for improved diagnostic methods to 
distinguish invasive adenomas from pituitary carcinomas in their sellar phase. Due to 
differences in prognosis between invasive adenoma and pituitary carcinoma, earlier 
diagnosis with treatment modification could potentially result in improved outcomes for 
these patients.
Accordingly, based on the findings of our study as well as review of the current literature, 
we suggest an aggressive management strategy for these patients. Such a strategy would 
likely include surgical resection of the primary tumor followed by determination of the 
Ki-67 index with or without identification of p53 expression to evaluate for malignant 
potential. Radiation therapy should be considered for those patients with high Ki-67 
percentage, especially for an incomplete surgical resection as invasive adenomas tend to 
reoccur multiple times [4, 33]. Although our results fail to show a statistically significant 
difference in overall survival between patients treated with radiation therapy and those who 
were not, there was a trend towards improved survival. Additionally, data in SEER was only 
available for external beam radiation therapy and not for newer technologies such as 
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stereotactic radiosurgery. Ultimately, prospective studies are needed to determine the best 
management strategy.
Conclusion
We use the SEER database to report patterns of care and compare survival outcomes 
according to patient characteristics, tumor characteristics, and treatment received in a large 
series of patients with invasive adenoma or pituitary carcinoma. These data demonstrate 
worse overall survival in patients with pituitary carcinoma compared to invasive adenoma, 
highlighting the need for improved means of differentiating between the two tumors to allow 
for earlier diagnosis and treatment modification.
Comments
Ludwig Benes, Arnsberg Germany
This well-written and interesting article deals with the rare pathologies of invasive pituitary 
adenomas and carcinomas collected over a 35-year time period. The data from a large series 
of 117 individuals suffering from these pathologies is illustrated comprehensively. 
Information is given regarding the role of genetic studies on this topic and also the 
prognostic significance of molecular markers. The authors nicely point out the differences in 
survival outcomes in these patients during a long follow-up period of 10 years underlining 
what most of the readers may have thought but could not really prove on the basis of a 
robust data analysis.
Paolo Cappabianca, Teresa Somma, Naples, Italy
The authors present a retrospective analysis pointing out the differences in terms of survival 
outcomes in patients with invasive pituitary adenomas and carcinomas over a 10-year 
follow-up period. Once again, the importance of early differential diagnosis has been 
emphasized to provide patients with an adequate treatment.
Though, this manuscript offers the possibility to draw many considerations.
The invasive adenoma is identified as a benign pituitary tumor, even if it exhibits an 
aggressive biological behavior, infiltrating the dura mater, cranial bone, or sphenoid sinus. 
Our experience constantly teaches us to warn these “false benign” lesions; they, indeed, 
require difficult management to achieve an adequate disease control. The pituitary 
carcinoma is defined as a tumor of the pituitary gland exhibiting cerebrospinal and/or 
systemic metastasis.
In our opinion, clinical evaluation of the patient needs to be completed by head and spinal 
MR and total body PET/CT to diagnose the presence of eventual metastasis indicative of a 
neoplastic progression. The metastatic dissemination more commonly involves the CSF 
axis, including virtually any site within the supratentorial, infratentorial, and spinal 
compartments. Extradural dissemination occurs less frequently and also exhibits less 
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geographic restraint; bone, liver, lymph nodes, lung, kidney, and heart have all been 
reported as evidence of malignancy.
Furthermore, we believe that the genetic analysis can be useful not only to evaluate the 
biological behavior, as affirmed in the article, but also to define the therapeutic efficacy.
In the manuscript, the authors affirm the need of an aggressive treatment for these lesions.
We think that surgery must be completed by medical and radiation therapy.
The drug temozolomide has recently been documented to be effective against these lesions 
(1, 5, 7) especially if they show low levels of MGMT expression or present the 
immunopositivity of MSH6 (2, 4, 8), though new targeted therapies have been studied for 
lesions resistant to temozolomide (3, 6, 9). Finally, the radiotherapy plays an important role 
in the management of these lesions, especially in those of incomplete surgical resection and 
low effectiveness of medical treatment.
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Fig. 1. 
Overall survival (a) of all patients included in survival analysis in this study (N=90) and (b) 
in patients with invasive adenoma stratified by age <65 and age ≥65
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Table 1
Demographic characteristics of the 117 patients with pituitary invasive adenoma or carcinoma included in this 
study
Total (%)
N=117
Invasive
adenoma (%)
N=110
Pituitary
carcinoma (%)
N=7
Age
 <65 90 (77) 86 (78) 4 (57)
 ≥65 27 (23) 24 (22) 3 (43)
 Median (range) 52 (1−85+) 52.5 (1−85+) 63 (18−78)
Gender
 Male 55 (47) 52 (47) 3 (43)
 Female 62 (53) 58 (53) 4 (57)
Race
 White 91 (78) 86 (78) 5 (71)
 African-American 15 (13) 14 (13) 1 (14)
 American Indian/
  Alaskan Native
1 (1) 1 (1) 0 (0)
 Asian/Pacific Islander 7 (6) 6 (5) 1 (14)
 Unknown 3 (3) 3 (3) 0 (0)
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Table 2
Tumor histology based on ICD-0-3 codes and disease extent of the 117 pituitary tumors included in the study
Total (%) Invasive adenoma (%) Pituitary carcinoma (%)
Histologya (ICD-0-3 code) N=117 N=110 N=7
 Adenoma/adenocarcinoma, NOS (8140) 38 (32) 37 (34) 1 (14)
 Neuroendocrine adenoma/carcinoma (8246) 7 (6) 6 (5) 1 (14)
 Chromophobe adenoma/carcinoma (8270) 17 (15) 15 (14) 2 (29)
 Prolactinoma (8271) 1 (1) 1 (1) 0 (0)
 Pituitary adenoma/carcinoma, NOS (8272) 47 (40) 46 (42) 1 (14)
 Acidophil adenoma/carcinoma (8280) 7 (6) 5 (4) 2 (29)
Extent of diseaseb
 Localized, confined to gland of origin 14 (12) 14 (13) 0 (0)
 Localized NOS 28 (24) 28 (25) 0 (0)
 Invading adjacent connective tissue or organs 35 (30) 35 (32) 0 (0)
 Further contiguous extension 2 (2) 2 (2) 0 (0)
 Metastases 7 (6) 0 (0) 7 (100)
 Unknown 31 (26) 31 (28) 0 (0)
aAll tumors classified as adenoma or adenocarcinoma (M8140-M8389). Histologic sub-classifications within the larger grouping of adenoma/ 
adenocarcinoma based on ICD-0-3 codes in the SEER database
bOnly malignant tumors with documented metastases classified as pituitary carcinomas
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Table 3
Frequency of treatment with radiation therapy and/or surgery in our study population
Total (%) Invasive adenoma (%) Pituitary carcinoma (%)
Radiation therapy (RT) N=117 N=110 N=7
 External beam 34 (29) 33 (30) 1 (14)
 None 79 (68) 73 (66) 6 (86)
 Unknown 4 (3) 4 (4) 0 (0)
Surgery (1983+)a N=97 N=91 N=6
 Incisional, needle, or aspiration biopsy 2 (2) 2 (2) 0 (0)
 Simple tumor resection (STR) 60 (62) 58 (64) 2 (33)
 Gross tumor resection (GTR) 9 (9) 9 (10) 0 (0)
 None 29 (30) 26 (29) 3 (50)
 Unknown 17 (18) 15 (16) 2 (33)
Combination therapyb N=90 N=83 N=7
 STR alone 36 (40) 34 (41) 2 (29)
 STR + RT 20 (22) 20 (24) 0 (0)
 RT alone 3 (3) 2 (2) 1 (14)
 No STR or RT 10 (11) 8 (10) 2 (29)
 None of the above 21 (23) 19 (23) 2 (29)
aSurgical data available only from 1983–2008 (N=91 invasive adenomas, 6 carcinomas). Some patients received multiple surgical procedures. 
Description of surgical techniques in the “Methods” section
bNumbers included only those cases that met the inclusion and exclusion criteria for survival analysis (N=83 invasive adenomas, 7 carcinomas) 
listed in the “Methods” section
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Table 4
Five-year overall survival in patients with invasive adenoma (N=83) stratified by pituitary adenoma histologic 
subclassification according to ICD-0-3 codes
Overall survival (%)
Adenoma, NOS (8140) 86.6
Neuroendocrine adenoma (8246) 100
Chromophobe adenoma (8270) 71.2
Pituitary adenoma, NOS (8272) 69.7
Acidophil adenoma (8280) 80
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